ARRIVENT BIOPHARMA, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross
ARRIVENT BIOPHARMA, INC. (AVBP) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross of 3.28 million shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Shareholders' Equity
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross · last filed 2026-08-12
- ARRIVENT BIOPHARMA, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2026-06-30 was 334.25K shares, a 16.47% increase year-over-year.
- ARRIVENT BIOPHARMA, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2026-03-31 was 2.95M shares, a 84.63% increase year-over-year.
- ARRIVENT BIOPHARMA, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-12-31 was 170.00K shares, a 953.48% increase year-over-year.
- ARRIVENT BIOPHARMA, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-09-30 was 127.40K shares, a 31.05% increase year-over-year.
- ARRIVENT BIOPHARMA, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2025 was 2.18M shares, a 91.89% increase from fiscal 2024.
- ARRIVENT BIOPHARMA, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2024 was 1.14M shares, a 41.97% increase from fiscal 2023.
- ARRIVENT BIOPHARMA, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2023 was 801.09K shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 12 month |
|---|---|---|---|---|
| 2026-06-30 | 334.25K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | 3.28M shares 10-Q · filed 2026-08-12 | 3.45M shares derived: sum of 3 quarters · filed 2026-08-12 | 3.58M shares derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | 2.95M shares 10-Q · filed 2026-05-11 | 3.12M shares derived: sum of 2 quarters · filed 2026-05-11 | 3.25M shares derived: sum of 3 quarters · filed 2026-05-11 | 3.53M shares derived: sum of 4 quarters · filed 2026-05-11 |
| 2025-12-31 | 170.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | 297.40K shares derived: sum of 2 quarters · filed 2026-03-05 | 584.40K shares derived: sum of 3 quarters · filed 2026-03-05 | 2.18M shares 10-K · filed 2026-03-05 |
| 2025-09-30 | 127.40K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | 414.40K shares derived: sum of 2 quarters · filed 2025-11-10 | 2.01M shares 10-Q · filed 2025-11-10 | 2.03M shares derived: sum of 4 quarters · filed 2025-11-10 |
| 2025-06-30 | 286.99K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-11 | 1.88M shares 10-Q · filed 2025-08-11 | 1.90M shares derived: sum of 3 quarters · filed 2025-08-11 | 2.00M shares derived: sum of 4 quarters · filed 2025-08-11 |
| 2025-03-31 | 1.60M shares 10-Q · filed 2025-05-12 | 1.61M shares derived: sum of 2 quarters · filed 2025-05-12 | 1.71M shares derived: sum of 3 quarters · filed 2025-05-12 | 1.85M shares derived: sum of 4 quarters · filed 2025-05-12 |
| 2024-12-31 | 16.14K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | 113.36K shares derived: sum of 2 quarters · filed 2025-03-03 | 250.53K shares derived: sum of 3 quarters · filed 2025-03-03 | 1.14M shares 10-K · filed 2025-03-03 |
| 2024-09-30 | 97.22K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | 234.39K shares derived: sum of 2 quarters · filed 2024-11-14 | 1.12M shares 10-Q · filed 2024-11-14 | |
| 2024-06-30 | 137.18K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | 1.02M shares 10-Q · filed 2024-08-14 | ||
| 2024-03-31 | 886.78K shares 10-Q · filed 2024-05-08 | |||
| 2023-12-31 | 801.09K shares 10-K · filed 2025-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |